Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0229

Scientific exchange · Dr. Gabriel Kimura

25 Jan 2026 · Virtual · Dr. Gabriel Kimura, UCLH · MSL Rachel Adeyemi · Aurelin

ReviewedManualENG-0229MI request

Capture insight from this engagement

Location: UCLH
Therapeutic area: Immunology
Country: United Kingdom
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Aurelin (aurelinate)

Topics discussed

Adolescent population

Scientific content used

JAK selectivity review

Questions raised

When will adolescent data be available?

Notes

Scientific exchange with dermatologist at UCLH. Discussed adolescent population.

Insights captured (1)

Capture insight

INS-0041High
Adolescent population
Adolescent population: recurring question reported by dermatologist (GB).
Closed

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 3
Depth of exchange: 2
Actionability: 3

Data lineage

Source system: Manual
Sync: Entered manually in Hub
System of record: Hub
Record id: ENG-0229

Audit history (0)

All create, update and approval events for this record

No audit events in sample data